Precision Optics Stock Price, News & Analysis

Precision Optics (Nasdaq: POCI) has launched the Unity Imaging Platform, a standardized CMOS endoscopic system with customization options for medical, industrial, and defense applications. The platform represents a significant shift from traditional custom-built solutions, offering a modular architecture suitable for both reusable and single-use endoscopic systems.

The Unity platform aims to transform endoscopic imaging device development by reducing costs, development time, and project risks through pre-validated design elements and proven architectures. Key benefits include accelerated time to market, cost efficiency, risk mitigation, and scalability for product portfolios.

The company currently has two single-use endoscope programs in production, with more in development. Future platform expansions will include advanced capabilities such as multi-sensor imaging for 3D and fluorescence applications.

Precision Optics (POCI) has received a $340,000 initial production order for a new single-use ophthalmic endoscope from a major global medical device company. Production will start in January 2025, with delivery over five months to support a June 2025 product launch. Follow-on orders are expected at 2-3x the initial rate. This represents the second single-use program moving to production this year, following a $9 million cystoscope imaging assembly order. The new product replaces an existing reusable endoscope system with improved image quality and single-use functionality.

Precision Optics (NASDAQ: POCI) reported Q1 FY2025 financial results with revenue of $4.2 million, slightly down from $4.3 million in Q1 FY2024. The company experienced decreased gross margins of 26.6% compared to 33.9% year-over-year, and reported a net loss of $1.3 million. Engineering revenue remained stable at $1.9 million, while production revenue slightly decreased to $2.3 million. Notable developments include accelerated production deliveries for a $9 million urological endoscope order and a new $340,000 production order for single-use ophthalmic endoscopes, with expectations of substantial revenue growth in Q2 FY2025.

Precision Optics (Nasdaq: POCI), a designer and manufacturer of advanced optical instruments for medical and defense/aerospace industries, has scheduled a conference call for November 14, 2024, at 5:00pm ET to discuss first quarter fiscal year 2025 financial results. The company will release its financial results and file its 10-Q after market close on the same day. Interested parties can join via phone at (844) 735-3662 or (412) 317-5705, or through a live webcast. A replay will be available until November 21, 2024.

Precision Optics (NASDAQ: POCI) announced that its customer, a surgical robotics company, received FDA 510(k) clearance for its AI-powered platform treating Benign Prostate Hyperplasia. POC designs and manufactures the single-use endoscope imaging assembly for this system. The company has begun production deliveries against a $9 million order, with estimated deliveries of $3.6 million during fiscal year ending June 2025. POC expects significant long-term growth as their customer deploys the new robotic system in the market where they already hold a dominant position.

Precision Optics (Nasdaq: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, has announced its participation in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024. The company will engage in two key activities:

1. A webcast presentation scheduled for 1:15 pm ET, accessible via the conference homepage or a direct link.

2. Virtual one-on-one meetings with investors throughout the event.

Interested parties can access the webcast through the provided links, with a replay option available post-event. To arrange one-on-one meetings, investors can contact Lytham Partners directly or register for the event through the given link.

Precision Optics (NASDAQ: POCI) reported its Q4 and fiscal year 2024 results. FY 2024 revenue was $19.1 million, down from $21.0 million in FY 2023, but exceeding the high-end guidance. Production revenue decreased 25% to $10.8 million, while engineering revenue increased 24% to a record $8.3 million. The company reported a net loss of $3.0 million compared to a $0.1 million loss in the previous year.

For Q4 FY2024, revenue was $4.7 million, down from $5.0 million in Q4 FY2023. The company received a $9 million production order for a high-volume single-use cystoscopy surgery program in May 2024. Despite facing the loss of several significant programs, Precision Optics backfilled a portion of the shortfall with record product development revenue. The company expects double-digit revenue growth for fiscal 2025, with significant increases beginning in Q2 FY2025.

Precision Optics (Nasdaq: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, has announced a conference call to discuss its fourth quarter and fiscal year 2024 financial results. The call is scheduled for Monday, September 30, 2024, at 5:00pm ET.

The company plans to release its financial results and file its 10-K after the market closes on the same day. Interested parties can join the call by dialing (844) 735-3662 or (412) 317-5705. A live webcast will also be available at https://app.webinar.net/0Aa98ozwG53. A teleconference replay will be accessible until October 7, 2024, and a webcast replay will be available at the same link.

Precision Optics (NASDAQ: POCI) has announced a $1.4 million registered direct offering of common stock. The company will sell 265,868 shares at $5.25 per share to institutional and accredited investors, and $5.79 per share to directors and officers. The offering is expected to close on August 15, 2024, subject to customary conditions. A.G.P./Alliance Global Partners is acting as the sole placement agent. The offering is made pursuant to an effective shelf registration statement on Form S-3. Proceeds will be used for general corporate purposes, potentially including working capital, capital expenditures, and business development activities.